RO7268489
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RO7268489, covering 2026-04-23 to 2026-04-23. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) [Phase 2]